Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Gastroesophageal Reflux, Apnea, Bradycardia
Interventions: Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W); Drug · Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Days and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Menopausal Syndrome
Interventions: Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Candidiasis
Interventions: Caspofungin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Major Depressive Disorder
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions: Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 12,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 135
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more

Conditions: Acute Kidney Injury
Interventions: Amino Acids, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy
Interventions: Coffee, Decaffeinated coffee; Dietary Supplement
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Exogenous Ketosis
Interventions: KE1 5g, KE1 10g, KE4 5g, KE 10g, Placebo drink; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 25 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Parkinson's Disease
Interventions: RO7046015, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more

Conditions: Menopause, Cognitive Disturbances
Interventions: atomoxetine, placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Overweight
Interventions: Leptin, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome, Guyon's Canal, Dupuytren Contracture, Morton Neuroma, Tarsal Tunnel Syndrome, Plantar Fasciopathy, Peroneal Nerve Entrapment
Interventions: NAC, NAC 0mg/day (Placebo); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Herpes Simplex Type II
Interventions: TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Curcumin, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 25 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions: recombinant human CC10 (rhCC10), placebo; Drug
Lead sponsor: Clarassance, Inc.; Industry
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 4
States / cities: Wilmington, Delaware • Baltimore, Maryland • Mineola, New York

Conditions: Covid19, SARS-CoV Infection
Interventions: Sargramostim, Placebo; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more

Conditions: Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions: omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 3
States / cities: Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin

Conditions: Autism Spectrum Disorder
Interventions: Sulforaphane, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 3 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Bronchopulmonary Dysplasia
Interventions: Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 7 Days to 28 Days
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Little Rock, Arkansas • Loma Linda, California • Jacksonville, Florida + 17 more

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more

Conditions: Cystic Fibrosis
Interventions: Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 5 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 82
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more

Search by objective public record fields.

Study of Erythromycin in GER-Associated Apnea of the Newborn

Early Menopause Hormone Treatment and Cognition

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Amino Acids for Cardiac Surgery Associated AKI

The Effects of Caffeine on Human Spinal Motoneurons

Acceptability and Tolerability of Ketone Supplements and Effects of BHB Concentrations in Young Adults

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

Trial of Leptin Administration After Roux-en-Y Gastric Bypass

NAC-REPAIR for Post-surgical Pain

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

The Impact of Perioperative Ketamine Infusion on Surgical Recovery

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

Sargramostim Use in COVID-19 to Recover Patient Health

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease